Adjuvant chemotherapy for non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 5 SUPPL.1, 2007, Pages S7-

  Bria, Emilio ^a   Cuppone, Federica ^a   Cecere, Fabiana Letizia ^a   Milella, Michele ^a   Nisticò, Cecilia ^a   Cognetti, Francesco ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; META ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; VINBLASTINE;

EID: 34250356427     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000268633.87529.75     Document Type: Conference Paper

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Johnson BE. Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. J Natl Cancer Inst 2003;95:1422-1424.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
4. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771.
5. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257-263.
6. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small-Cell Lung Cancer Collaborative Group. Bmj 1995;311:899-909.
7. Bria E, Gralla RJ, Raftopoulos H, et al. Randomized trials of supportive care (SC) versus chemotherapy in non-small-cell lung cancer (NSCLC): analysis of 16 trials with 2405 patients, Proceedings of American Society of Clinical Oncology Annual Meeting (ASCO). Orlando, FL. J Clin Oncol 2002;20:325a.
8. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
9. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
10. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222.
11. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
12. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uraciltegafur chemotherapy increased survival of patients with completely resected p-stage I non-small-cell lung cancer. Lung Cancer 2005;49:85-94.
13. Nakagawa K, Tada H, Akashi A, et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small-cell lung cancer. Br J Cancer 2006;95:817-821.
14. Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: long-term survival in a randomized study. Int J Cancer 2006;119:955-960.
15. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small-cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. Proceedings of American Society of Clinical Oncology Meeting. Post meeting edition. J Clin Oncol 2006;24:7007.
16. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small-cell lung cancer (JCOG9304). Lung Cancer 2004;43:167-173.
17. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small-cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
18. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
19. Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 2000;113:617-620.
20. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
21. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small-cell lung cancer. Ann Oncol 2005;16:1069-1075.
22. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. Proceedings of American Society of Clinical Oncology Meeting. Post meeting edition. J Clin Oncol 2006;24:7008.
23. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2001;2:475-482.
24. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006;354:1667-1669.
25. Raftopoulos H, Gralla RJ, D'Auria G, et al. Assessing the role of cisplatin dose and dose intensity (DI) in advanced non-small-cell lung cancer (NSCLC): A comprehensive review of randomized trials 1992-2002, Proceedings of America Society of Clinical Oncology Meeting (ASCO). Chicago (IL, US), J Clin Oncol 2003;21:2321.
26. Bria E, Giannarelli D, Terzoli E. Treatment of resected non-small-cell lung cancer. N Engl J Med 2005;353:1523-1524; author reply 1523-1524.
27. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-3867.
28. Sedrakyan A, Van Der Meulen J, O'Byrne K et al. Postoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414-419.
29. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small-cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
30. Bria E, Gralla RJ, Raftopoulos H, et al. Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. J Clin Oncol 2005;23:7140.
31. National Cancer Institute. Levels of Evidence for Adult Cancer Treatment Studies, Health Professional Version (last modified 2004). Available at: http://www.cancer.gov. Accessed March 19, 2004.
32. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004;22:3839-3841.
33. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006;355:1054-1055.
34. Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 2005;11:8341-8347.
35. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
36. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
37. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.